第8版国际肺癌TNM分期标准修订稿解读  

Proposals for revisions of the TNM descriptors in the eighth edition of the TNM classification for lung cancer

作　　者：张旻[1] 费霞[1] 周新[1] 

机构地区：[1]上海交通大学附属第一人民医院呼吸科,上海200080

出　　处：《世界临床药物》2016年第7期441-445,共5页World Clinical Drug

基　　金：国家自然科学基金资助项目(编号:81100033)

摘　　要：在国际肺癌协会(IASLC)肺癌TNM分期第7版基础上,结合收集的1999-2010年期间16个国家35个中心94 708例病例中的77 156例数据的分析结果,重新修订了TNM分期,即第8版TNM分期。新分期的实施将为肺癌的预后判断提供更有效的临床依据。本文就第8版国际肺癌TNM分期标准修订稿的变更内容、修改依据及局限性作一解读。The new database of the International Association for the Study of Lung Cancer （IASLC） consists of 94 708 new patients diagnosed as lung cancer during 1999 - 2010 from 35 sources in 16 countries. The database published in 2016 analyzes the TNM classification of lung cancer, which is beneficial for clinical evaluation of lung cancer. This review describes some content change, amending and limitations in eighth edition of TNM classification for lung cancer.

关 键 词：肺癌 TNM分期 解读 

分 类 号：R734.2[医药卫生—肿瘤]